Shots:

• The company launches its first oncology treatment Ontruzant (trastuzumab)- a biosimilar referencing Herceptin in Brazil. The biosimilar has received ANVISA’s approval for the treatment of metastatic HER2-overexpressing BC- early HER2-overexpressing BC- and advanced gastric cancer
• Ontruzant is being supplied to SUS through a PDP b/w Samsung Bioepis & Bionovis and Bio-Manguinhos. This the second product to be launched in Brazil followed by Brenzys- both in partnership with local partners
• Ontruzant is now available in six markets: Brazil- Australia- EU- the US- Ukraine and Korea. The therapy has received EC’s MAA in Nov’2017 and the US FDA’s approval in Jan’2019

­ Ref: Samsung Bioepis | Image: Samsung Bioepis